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doi:10.1Objective: Radiofrequency ablation for Barrett’s esophagus in combination with an antireflux procedure has not
been widely documented. We report our initial experience with radiofrequency ablation in association with anti-
reflux procedure for Barrett’s metaplasia and low-grade dysplasia.
Methods: A total of 14 patients (10 male and 4 female patients) presented with Barrett’s metaplasia (n¼ 11) or
low-grade dysplasia (n¼ 3). Median age was 60 years (38–80 years). The severity of Barrett’s esophagus was
classified by length (in centimeters), appearance (circumferential/noncircumferential), and histology (1, normal;
2, Barrett’s metaplasia; and 3, low-grade dysplasia). Radiofrequency ablation was performed with the HALO
360 or 90 systems (BARRX Medical, Sunnyvale, Calif).
Results: Median follow-up was 17 months. The mean number of ablative procedures undertaken was 2.6 (range,
1–6). There was no mortality, but there were 2 perioperative complications after the antireflux procedure (pneu-
monia, 1; atrial fibrillation, 1). One patient had mild dysphagia requiring a single dilation 2 months after ablation.
The mean length of Barrett’s esophagus decreased from 6.2 to 1.2 cm after treatment (P¼ .001). Barrett’s grade
decreased significantly (P¼ .003). Before therapy, circumferential Barrett’s esophagus was present in 13 pa-
tients. At last endoscopy, only 1 patient had circumferential Barrett’s esophagus present. The number of radio-
frequency ablation treatments was significantly (P< .05) associated with success. All patients receiving 3 or
more treatments had complete resolution of Barrett’s metaplasia.
Conclusions: Radiofrequency ablation performed either before or after an antireflux procedure is safe. This ap-
proach is effective for reducing or eliminating metaplasia and dysplasia. Long-term studies will be necessary to
determine whether this approach can provide durable control of both reflux and Barrett’s esophagus. (J Thorac
Cardiovasc Surg 2010;139:713-6)E
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SLongstanding gastroesophageal reflux disease (GERD) has
been documented as an important risk factor for esophageal
adenocarcinoma.1 Patients with GERD are at risk of present-
ing with esophageal mucosal abnormalities ranging from
simple Barrett’s metaplasia to low- or high-grade dysplasia,
with adenocarcinoma culminating the disease spectrum.2
The prevalence of Barrett’s esophagus in a general adult
population is estimated to be around 0.4% to 1.6%.3 In
a high-risk population with chronic GERD, the incidence
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The Journal of Thoracic and CaBarrett’s metaplasia has an estimated risk of progression to
cancer of 0.5% to 1.0% per patient-year of follow-up.
Because of the risk for dysplasia and adenocarcinoma, endo-
scopic surveillance is recommended when Barrett’s esopha-
gus is present. The usual recommendation for surveillance
endoscopy is every 3 years for metaplasia and yearly endos-
copy for low-grade dysplasia.5
Radiofrequency ablation (RFA) of the esophageal mucosa
has been gaining increasing popularity for treatment of
esophageal dysplasia. RFA appears to be effective and
well tolerated with minimal morbidity and, unlike some
other mucosal ablation modalities, has been claimed to be
associated with no buried glands after squamous re-epitheli-
alization of the esophagus. For this reason, several centers
are starting to use RFA for the treatment of nondysplastic
Barrett’s esophagus.6,7 The evidence supporting the routine
use of fundoplication for Barrett’s metaplasia and dysplasia
is inconclusive, although some small series have demon-
strated regression after fundoplication, particularly for pa-
tients with short-segment disease.8,9 In theory combining
an antireflux procedure with mucosal ablation of Barrett’s
changes should provide superior control of Barrett’s changes
by eliminating or decreasing the high-risk metaplastic orrdiovascular Surgery c Volume 139, Number 3 713
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GERD ¼ gastroesophageal reflux disease
RFA ¼ radiofrequency ablation
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Sdysplastic mucosa and decreasing further acid injury to the
esophagus. We report our early experience with this com-
bined approach. The primary goals are to demonstrate safety
and feasibility and to report short-term outcomes.MATERIALS AND METHODS
Patients with symptomatic GERD (on medical therapy) and evidence of
Barrett’s metaplasia or low-grade dysplasia were offered RFA and an anti-
reflux procedure. Our current protocol is to initially perform RFA and then
re-evaluate at 6 weeks. If further Barrett’s esophagus is present, patients are
retreated at least 1 more time and then undergo an antireflux operation 6
weeks later. After 3 months, repeat endoscopy is undertaken, as well as fur-
ther RFA, if necessary. Some patients underwent fundoplication before
RFA, and this included patients with symptomatic giant hiatal hernias and
patients who had undergone fundoplication at other institutions. RFA was
undertaken no sooner than 3 months after fundoplication. We do not offer
fundoplication to patients whose symptoms are well controlled with medi-
cations. Fundoplication is only offered to symptomatic patients. This report
does not include asymptomatic patients treated with RFA alone.
The study was undertaken in 2 institutions, and institutional review
board approval was present in both centers. This was a retrospective analy-
sis of data collected from prospective registries in both centers. We recorded
and compared the following endoscopic findings before and after therapy:
(1) the length of Barrett’s esophagus, (2) the appearance of the Barrett’s
esophagus (circumferential/noncircumferential), and (3) the severity of
the histologic findings. To enable comparison of these endoscopic findings,
we graded the appearance of the Barrett’s esophagus as follows: 1, no Bar-
rett’s; 2, single island; 3, noncircumferential or multiple islands; and 4, cir-
cumferential. Histologic findings are graded in the registry as follows: 1,
normal mucosa; 2, Barrett’s metaplasia; 3, low-grade dysplasia; 4, high-
grade dysplasia; and 5, cancer. However, in the current report there are
no patients with high-grade dysplasia or cancer. Surveillance endoscopy in-
cluded 4 quadrant biopsies performed every 2 cm along the length of the
previously noted Barrett’s changes. All data were entered into an SPSS
file (version 14.0 for Windows; SPSS, Inc, Chicago, Ill), and analysis
included paired t test analysis of pretreatment and posttreatment endoscopic
findings.
An upper endoscopy was performed to determine the location of the most
proximal extent of contiguous Barrett’s esophagus and the top of the gastric
folds to guide catheter placement. Before ablation, the esophagus was irri-
gated with acetylcysteine solution 20% (200 mg/mL) mixed in plain water
as a mucolytic to provide a direct contact surface between the lesion and the
RFA device. After lesion mapping, a metal guide wire was introduced
through the endoscope for the subsequent introduction of a sizing balloon
and then insertion of a HALO 360 device. For short-segment noncircumfer-
ential Barrett’s esophagus or for islands of Barrett’s esophagus, the HALO
90 device was used. The detailed technique for the RFA has been previously
described.10 All procedures were performed after achievement of general
anesthesia.RESULTS
From May 2006 to August 2008, 14 patients were treated
with this protocol. The median age was 62 years (range, 38–
80 years). This included 10 male and 4 female patients.714 The Journal of Thoracic and Cardiovascular SurgEleven patients had metaplasia only, and 3 had low-grade
dysplasia. The median follow-up was 17 months (range,
3–33 months). The median number of RFA treatments was
2 (range, 1–6).
The mean length of Barrett’s esophagus decreased signifi-
cantly (P¼ .001), from 6.4 cm (range, 1–12 cm) to 1.2 cm
(range, 0–5 cm). This corresponded to a median decrease of
93% compared with the original length of Barrett’s esophagus.
Before therapy, 13 of 14 patients had circumferential Bar-
rett’s esophagus (mean grade, 3.8). After therapy, only 1 pa-
tient had circumferential Barrett’s esophagus (mean grade,
1.7), representing a significant (P¼ .001) improvement in
the endoscopic appearance of the Barrett’s esophagus. The
one patient with persistent circumferential Barrett’s esopha-
gus originally presented with a 10-cm segment of Barrett’s
esophagus and a giant hiatal hernia. After laparoscopic repair
of his hiatal hernia, 2 RFA treatments have been performed,
with reduction in the length of Barrett’s esophagus to 5 cm.
Histologic severity also improved significantly
(P¼ .003), with the mean grade improving from 2.2 to
1.5. Before therapy, 3 patients had low-grade dysplasia,
and 11 had metaplasia. After therapy, there were 7
(50.0%) patients with persistent Barrett’s metaplasia only
and 7 (50.0%) patients with complete resolution of the Bar-
rett’s metaplasia. The number of treatments was signifi-
cantly associated with successful improvement in the
length (P¼ .017), appearance (P¼ .037), and histologic
severity (P¼ .001). All patients with 3 or more RFA treat-
ments had complete resolution of metaplasia and dysplasia.
Eleven patients underwent laparoscopic fundoplication,
and 3 patients underwent endoscopic fundoplication with
the NDO plicator (n¼ 2; NDO Surgical, Mansfield, Mass)
or the Esophyx system (n¼ 1; EndoGastric Solutions, Red-
mond, Wash). Mucosal ablation both before and after the
antireflux operation was undertaken in 4 patients.
There were no deaths, but there were 2 perioperative com-
plications after an antireflux procedure. One patient had
atrial fibrillation, which resolved in the hospital, and the sec-
ond patient had pneumonia after repair of a giant hiatal her-
nia. Additionally, one other patient had mild dysphagia
requiring dilation 2 months after mucosal ablation and
previous fundoplication. The single esophageal dilation
resulted in complete resolution of his symptoms.
DISCUSSION
Endoscopic mucosal ablation of the esophagus has been
increasingly reported since 1992 with the work of Brandt
and Kauvar11 and Berenson and colleagues,12 who demon-
strated esophageal re-epithelialization after therapeutic in-
jury to the metaplastic epithelium.
Currently, mucosal ablation is regarded as an option for
selected patients with high-grade dysplasia and even for
early adenocarcinoma.13 Photodynamic therapy, the most
widely reported ablative modality, has been proved to beery c March 2010
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and side effects characterized by strictures and photosensi-
tivity make the use of photodynamic therapy practically pro-
hibitive for simple Barrett’s metaplasia, a relatively benign
condition compared with high-grade dysplasia.
Several studies have reported on a variety of ablation
methods and have demonstrated difficulty in achieving com-
plete eradication of Barrett’s metaplasia.15-17 Although
many questions still remain without answers, eradication
of Barrett’s esophagus has moved from a concept to reality
in recent years. In a study with 100 patients, circumferential
ablation of nondysplastic Barrett’s esophagus with a bal-
loon-based RFA device was performed with no subsequent
strictures and with complete elimination of Barrett’s esoph-
agus in 70% of patients at 1 year’s follow-up, proving this to
be a safe and effective method for ablation of Barrett’s meta-
plasia.7 A subsequent smaller study of only 11 patients but
with longer follow-up (2.5 years) demonstrated complete
eradication of Barrett’s metaplasia in 98% of patients using
the same protocol for RFA. A complete remission of dyspla-
sia and complete endoscopic and histologic removal of Bar-
rett’s esophagus was 100% achieved. There were no adverse
events or strictures in this series.18
The role of RFA for dysplastic Barrett’s metaplasia is
becoming more established. In a recent multi-institutional
randomized study,19 127 patients were assigned to receive
either RFA (ablation group) or a sham procedure (control
group). Among patients with low-grade dysplasia, complete
eradication occurred in 90.5% of those in the ablation group
compared with 22.7% of those in the control group (P<
.001). Similar results were observed among patients with
high-grade dysplasia (81% eradication vs 19% in the con-
trol group, P< .001). Overall, complete eradication of Bar-
rett’s esophagus occurred at a rate of 77.4% compared with
2.3% of those in the control group. A lower incidence of
cancer and less disease progression were also positive ef-
fects of ablation compared with the sham procedure.
Our preliminary data demonstrates a 50% complete re-
mission rate of Barrett’s esophagus, which is lower than
that reported in the above studies. This might be explained
in part by a lower number of treatments in our series (me-
dian, 2) compared with that seen in a recent randomized
study in which a mean of 3.5 treatments were used.19 In
our series any patient who received 3 or more ablation ther-
apies achieved 100% control of metaplasia or dysplasia. All
patients are still under surveillance, and further treatments
will be performed for refractory Barrett’s esophagus. An-
other factor is that we have not excluded any patients based
on the length of Barrett’s esophagus, whereas previous stud-
ies have excluded patients with longer segments of Barrett’s
esophagus.
Antireflux surgery is usually performed to control reflux
symptoms; however, it might also prevent progression and
possibly result in regression of dysplastic and metaplasticThe Journal of Thoracic and Cachanges in the esophagus. This is, however, difficult to
prove, and the evidence supporting this is inconclusive. A
retrospective study of 49 patients who underwent fundopli-
cation for GERD complicated with Barrett’s esophagus
demonstrated 18% of patients with mucosal normalization
at a median follow-up of 18 months; however, progression
to adenocarcinoma in situ was also observed in 1 patient
in this series.20
In another study with 97 patients with Barrett’s esophagus
undergoing fundoplication; 79% of patients were asymp-
tomatic after surgical intervention. Low-grade dysplasia
regressed to nondysplastic metaplasia in 44% of (7/16)
patients, and metaplasia regressed to normal squamous
mucosa in 14% (9/63) of patients. Of note, 6% of patients
progressed to low-grade dysplasia, but no patient had
high-grade dysplasia or cancer in 410 patient-years of
follow-up in this series.21
This report describes a new clinical pathway for Barrett’s
esophagus, offering patients a combination of 2 treatment
modalities: RFA of abnormal esophageal mucosa and an
antireflux procedure to minimize continuing acid injury to
the esophagus. This approach theoretically should allow
optimal healing and minimize progression to cancer. Al-
though we have demonstrated that this combined approach
can be undertaken safely, the small number of patients and
short follow-up cannot address the question of long-term
success. Patients will still need continued surveillance until
further data are available. The increasing incidence of esoph-
ageal adenocarcinoma over the last few decades22 and the
relative mortality associated with this indicate the need for
a different approach for the prevention of cancer.
Our preliminary results with this new paradigm ap-
proach demonstrate its safety and possible effectiveness
to treat Barrett’s esophagus in patients with symptomatic
GERD. Further evaluation with larger controlled trials
will be necessary to better define the success and durability
of this approach for preventing progression to esophageal
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